Recruiting
Investigational
Study on N-Acetyl-L-Leucine for Patients with Niemann-Pick Disease Type C
Investigational
- Substances:L-Acetylleucine
Countries:
Czechia
Czechia- Participants:0–17 years · 18–64 years
- Substances:L-Acetylleucine
Find therapies in clinical trials near you – page 245
- recruiting
- 3 961
- countries
- 28
- conditions
- 2 103
3 961 trials recruiting28 European countries2 103 conditions coveredUpdated today
10 273 trials match your criteria
Recruiting
Investigational
Study on the Effectiveness and Safety of NS-229 for Patients with Eosinophilic Granulomatosis with Polyangiitis
Investigational
- Disease:Eosinophilic granulomatosis with polyangiitis
- Substances:Methyl-(1-{[6-{[(1S)-1-Cyclopropylethyl]Amino}-2-(Pyrazolo[5,1-B][1,3]Thiazol-7-Yl)-Pyrimidin-4-Yl]Carbonyl}Piperidin-4-Yl)Carbamate-Mono(4-Methylbenzenesulfonate) Monohydrate
Countries:
France
France- Participants:18–64 years · 65+ years
- Substances:Methyl-(1-{[6-{[(1S)-1-Cyclopropylethyl]Amino}-2-(Pyrazolo[5,1-B][1,3]Thiazol-7-Yl)-Pyrimidin-4-Yl]Carbonyl}Piperidin-4-Yl)Carbamate-Mono(4-Methylbenzenesulfonate) Monohydrate
Recruiting
B-cell lymphoma
RecruitingRegistered drugNo placebo
Study on Glofitamab and Drug Combination for Children and Young Adults with Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma
Registered drugNo placebo
- Disease:B-cell lymphoma
- Substances:CarboplatinEtoposide+5
Countries:Czechia
Czechia- Participants:0–17 years · 18–64 years
- Substances:Carboplatin
Recruiting
Diabetes mellitus+1
RecruitingRegistered drug
Study of Denosumab Effects on Muscle Strength and Insulin Sensitivity in Patients with Postmenopausal Osteoporosis and Diabetes Mellitus
Registered drug
- Disease:Diabetes mellitusOsteoporosis postmenopausal
- Substances:DenosumabSaline
Countries:
Denmark
Denmark- Participants:18–64 years
- Substances:Denosumab
Recruiting
Chronic kidney disease+1
RecruitingInvestigationalNo placebo
Study on the Long-Term Safety of Finerenone with ACE Inhibitors or ARBs for Children and Young Adults with Chronic Kidney Disease and Proteinuria
InvestigationalNo placebo
- Disease:Chronic kidney diseaseProteinuria
- Substances:Finerenone
Countries:
Austria
Austria- Participants:0–17 years · 18–64 years
- Substances:Finerenone
Recruiting
Polycythaemia vera
RecruitingRegistered drugNo placebo
Study Comparing Givinostat and Hydroxyurea for Patients with High-Risk Polycythemia Vera
Registered drugNo placebo
- Disease:Polycythaemia vera
- Substances:Carbasalate CalciumEnoxaparin Sodium+4
Countries:Austria
Austria- Participants:18–64 years · 65+ years
- Substances:Carbasalate Calcium
Recruiting
Alpha-1 antitrypsin deficiency
RecruitingRegistered drug
Study on Fazirsiran for Patients with Alpha-1 Antitrypsin Deficiency Liver Disease and Mild Fibrosis
Registered drug
- Disease:Alpha-1 antitrypsin deficiency
- Substances:FazirsiranSaline
Countries:Austria
Austria- Participants:18–64 years · 65+ years
- Substances:Fazirsiran
Recruiting
Procedural pain
RecruitingRegistered drug
Study on the Effect of Ketoprofen and Drug Combination for Managing Pain After Heart Surgery in Patients
Registered drug
- Disease:Procedural pain
- Substances:KetoprofenNefopam+3
Countries:France
France- Participants:18–64 years · 65+ years
- Substances:Ketoprofen
Recruiting
Neoplasm malignant+7
RecruitingRegistered drugNo placebo
Study on the Safety and Effects of XL092 with Nivolumab, Ipilimumab, and Relatlimab for Patients with Advanced Solid Tumors
Registered drugNo placebo
- Disease:Neoplasm malignantNeoplasm+6
- Substances:IpilimumabNivolumab+2
Countries:Austria
Austria- Participants:18–64 years · 65+ years
- Substances:Ipilimumab
Recruiting
Cardiac failure chronic+1
RecruitingRegistered drugNo placebo
Study on Meldonium and Physical Activity for Patients with Heart Failure with Preserved Ejection Fraction
Registered drugNo placebo
Countries:
Latvia
Latvia- Participants:18–64 years · 65+ years
- Substances:Meldonium
Recruiting
Triple negative breast cancer+4
RecruitingRegistered drugNo placebo
Study Comparing Sacituzumab Govitecan Alone and with Pembrolizumab for Patients with Low-Risk, Triple-Negative Early Breast Cancer
Registered drugNo placebo
- Disease:Triple negative breast cancerBreast cancer stage II+3
- Substances:PembrolizumabSacituzumab Govitecan
Countries:
Germany
Germany- Participants:18–64 years · 65+ years
- Substances:Pembrolizumab
Recruiting
Acute graft versus host disease
RecruitingRegistered drugNo placebo
Study on Mesenchymal Stromal Cells (MC0518) for Treating Steroid-Resistant Acute Graft Versus Host Disease in Adults and Adolescents
Registered drugNo placebo
- Disease:Acute graft versus host disease
- Substances:EverolimusMycophenolic Acid+2
Countries:France
France- Participants:0–17 years · 18–64 years · 65+ years
- Substances:Everolimus
